Comparison of different diagnostic tests

A comparison of the Fluorescence in-situ hybridization (FISH) test andĀ ALK immunohistochemistry (IHC) for determining ALK + status.

Basically the tests have results that are 99% consistent. The authors argue that either test should be sufficient on its own to determine if a patient is eligible for treatment by any of the ALK inhibitors.

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research. Bookmark the permalink.

Leave a Reply